Skip to main content
. 2020 Nov 18;8(11):513. doi: 10.3390/biomedicines8110513

Figure 1.

Figure 1

Effect of representative of anti-MAP therapy (RHB-104) and its major components on Mycobacterium avium subspecies paratuberculosis (MAP) viability in infected macrophages. MAP viability was measured in infected macrophages following treatment with RHB-104 (0, 0.5, 1.0, 2.0 μg/mL) (A), clarithromycin (CLA) (0, 0.32, 0.63, and 1.26 μg/mL) (B), and rifabutin (RIF) (0, 0.15, 0.30, 0.60 μg/mL) (C). * p < 0.05.